Natasha K Martin

List of Publications by Year
in descending order

109 papers	7,131 citations	109321 35 h-index	60623 81 g-index
109 all docs	109 docs citations	109 times ranked	8199 citing authors

#	Article	IF	Citations
1	The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet, The, 2016, 388, 1081-1088.	13.7	1,080
2	Public health and international drug policy. Lancet, The, 2016, 387, 1427-1480.	13.7	460
3	Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology, 2013, 58, 1598-1609.	7.3	431
4	Association of BCG, DTP, and measles containing vaccines with childhood mortality: systematic review. BMJ, The, 2016, 355, i5170.	6.0	415
5	Combination Interventions to Prevent HCV Transmission Among People Who Inject Drugs: Modeling the Impact of Antiviral Treatment, Needle and Syringe Programs, and Opiate Substitution Therapy. Clinical Infectious Diseases, 2013, 57, S39-S45.	5.8	275
6	The EASLâ€“Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet, The, 2022, 399, 61-116.	13.7	257
7	Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Societyâ€”Lancet Commission. Lancet, The, 2018, 392, 312-358.	13.7	230
8	The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia. Lancet, The, 2016, 388, 1228-1248.	13.7	213
9	Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. Journal of Hepatology, 2011, 54, 1137-1144.	3.7	199
10	Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology, 2012, 55, 49-57.	7.3	194
11	Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models. The Lancet Global Health, 2014, 2, e23-e34.	6.3	188
12	Responding to global stimulant use: challenges and opportunities. Lancet, The, 2019, 394, 1652-1667.	13.7	169
13	Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation. Journal of Hepatology, 2016, 65, 17-25.	3.7	157
14	Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM. Aids, 2013, 27, 2551-2557.	2.2	152
15	Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2018, 18, 1397-1409.	9.1	147
16	The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study. The Lancet Gastroenterology and Hepatology, 2019, 4, 435-444.	8.1	145
17	Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis <scp>C</scp> virus prevalence? Model projections for different epidemic settings. Addiction, 2012, 107, 1984-1995.	3.3	128
18	Can Hepatitis C Virus (HCV) Direct-Acting Antiviral Treatment as Prevention Reverse the HCV Epidemic Among Men Who Have Sex With Men in the United Kingdom? Epidemiological and Modeling Insights. Clinical Infectious Diseases, 2016, 62, 1072-1080.	5.8	122

#	Article	IF	Citations
19	The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and) Tj ETQq1 1 0.784314 rgBT /Over	3.8	119
20	Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe. Journal of Hepatology, 2018, 68, 402-411.	3.7	105
21	Rapid, Large-Scale Wastewater Surveillance and Automated Reporting System Enable Early Detection of Nearly 85% of COVID-19 Cases on a University Campus. MSystems, 2021, 6, e0079321.	3.8	94
22	Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework. Liver International, 2019, 39, 20-30.	3.9	88
23	Mathematical modelling of hepatitis C treatment for injecting drug users. Journal of Theoretical Biology, 2011, 274, 58-66.	1.7	86
24	Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland. Addiction, 2017, 112, 1302-1314.	3.3	80
25	Cost-effectiveness of HCV case-finding for people who inject drugs via dried blood spot testing in specialist addiction services and prisons. BMJ Open, 2013, 3, e003153.	1.9	74
26	Scalingâ€up HCV prevention and treatment interventions in rural United Statesâ€”model projections for tackling an increasing epidemic. Addiction, 2018, 113, 173-182.	3.3	71
27	Curbing the hepatitis C virus epidemic in Pakistan: the impact of scaling up treatment and prevention for achieving elimination. International Journal of Epidemiology, 2018, 47, 550-560.	1.9	64
28	Cost-effectiveness of Universal Hepatitis C Virus Screening of Pregnant Women in the United States. Clinical Infectious Diseases, 2019, 69, 1888-1895.	5.8	61
29	Is increased hepatitis C virus caseâ€finding combined with current or 8â€week to 12â€week directâ€acting antiviral therapy costâ€effective in UK prisons? A prevention benefit analysis. Hepatology, 2016, 63, 1796-1808.	7.3	58
30	The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments. BMC Medicine, 2015, 13, 198.	5.5	54
31	Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia. Medical Journal of Australia, 2012, 196, 638-641.	1.7	51
32	Treatment and primary prevention in people who inject drugs for chronic hepatitis C infection: is elimination possible in a high-prevalence setting?. Addiction, 2017, 112, 1290-1299.	3.3	42
33	The Potential Impact of a Hepatitis C Vaccine for People Who Inject Drugs: Is a Vaccine Needed in the Age of Direct-Acting Antivirals?. PLoS ONE, 2016, 11, e0156213.	2.5	41
34	Is the HCVâ€“HIV co-infection prevalence amongst injecting drug users a marker for the level of sexual and injection related HIV transmission?. Drug and Alcohol Dependence, 2013, 132, 172-181.	3.2	40
35	Is hepatitis C virus elimination possible among people living with <scp>HIV</scp> and what will it take to achieve it?. Journal of the International AIDS Society, 2018, 21, e25062.	3.0	39
36	Mathematical modeling of hepatitis c virus (HCV) prevention among people who inject drugs: A review of the literature and insights for elimination strategies. Journal of Theoretical Biology, 2019, 481, 194-201.	1.7	38

#	Article	IF	Citations
37	Optimal Control of Hepatitis C Antiviral Treatment Programme Delivery for Prevention amongst a Population of Injecting Drug Users. PLoS ONE, 2011, 6, e22309.	2.5	36
38	Prevalence and correlates of SARS-CoV-2 seropositivity among people who inject drugs in the San Diego-Tijuana border region. PLoS ONE, 2021, 16, e0260286.	2.5	35
39	Understanding the trends in HIV and hepatitis C prevalence amongst injecting drug users in different settingsâ€"Implications for intervention impact. Drug and Alcohol Dependence, 2012, 123, 122-131.	3.2	34
40	The effect of public health-oriented drug law reform on HIV incidence in people who inject drugs in Tijuana, Mexico: an epidemic modelling study. Lancet Public Health, The, 2018, 3, e429-e437.	10.0	33
41	Cost-Effectiveness of HBV and HCV Screening Strategies â€“ A Systematic Review of Existing Modelling Techniques. PLoS ONE, 2015, 10, e0145022.	2.5	32
42	Impact of current and scaledâ€up levels of hepatitis C prevention and treatment interventions for people who inject drugs in three UK settingsâ€"what is required to achieve the WHO's HCV elimination targets?. Addiction, 2018, 113, 1727-1738.	3.3	30
43	Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPITOPe) â€“ a natural experiment (protocol). BMJ Open, 2019, 9, e029538.	1.9	30
44	Potential impact of implementing and scaling up harm reduction and antiretroviral therapy on HIV prevalence and mortality and overdose deaths among people who inject drugs in two Russian cities: a modelling study. Lancet HIV,the, 2018, 5, e578-e587.	4.7	29
45	Scaling Up Hepatitis C Prevention and Treatment Interventions for Achieving Elimination in the United States: A Rural and Urban Comparison. American Journal of Epidemiology, 2019, 188, 1539-1551.	3.4	29
46	Evaluation of Severe Acute Respiratory Syndrome Coronavirus 2 Transmission Mitigation Strategies on a University Campus Using an Agent-Based Network Model. Clinical Infectious Diseases, 2021, 73, 1735-1741.	5.8	29
47	Behavioural, not biological, factors drive the HCV epidemic among HIV-positive MSM: HCV and HIV modelling analysis including HCV treatment-as-prevention impact. International Journal of Epidemiology, 2017, 46, 1582-1592.	1.9	25
48	Effects and cost of different strategies to eliminate hepatitis C virus transmission in Pakistan: a modelling analysis. The Lancet Global Health, 2020, 8, e440-e450.	6.3	25
49	Eliminating Hepatitis C Virus Among Human Immunodeficiency Virusâ€"Infected Men Who Have Sex With Men in Berlin: A Modeling Analysis. Journal of Infectious Diseases, 2019, 220, 1635-1644.	4.0	24
50	Primary Incidence of Hepatitis C Virus Infection Among HIV-Infected Men Who Have Sex With Men in San Diego, 2000â€"2015. Open Forum Infectious Diseases, 2019, 6, ofz160.	0.9	24
51	Modeling the impact of early antiretroviral therapy for adults coinfected with HIV and hepatitis B or C in South Africa. Aids, 2014, 28, S35-S46.	2.2	23
52	Identifying counties at risk of high overdose mortality burden during the emerging fentanyl epidemic in the USA: a predictive statistical modelling study. Lancet Public Health, The, 2021, 6, e720-e728.	10.0	22
53	Safe reopening of college campuses during COVID-19: The University of California experience in Fall 2020. PLoS ONE, 2021, 16, e0258738.	2.5	21
54	Cost of provision of opioid substitution therapy provision in Tijuana, Mexico. Harm Reduction Journal, 2018, 15, 28.	3.2	20

#	Article	IF	Citations
55	Estimating the contribution of stimulant injection to HIV and HCV epidemics among people who inject drugs and implications for harm reduction: A modeling analysis. Drug and Alcohol Dependence, 2020, 213, 108135.	3.2	20
56	HIV treatment as prevention among people who inject drugs â€“ a re-evaluation of the evidence. International Journal of Epidemiology, 2016, 46, dyw180.	1.9	19
57	Glucoseâ€“lactate metabolic cooperation in cancer: Insights from a spatial mathematical model and implications for targeted therapy. Journal of Theoretical Biology, 2014, 361, 190-203.	1.7	18
58	Opioid agonist treatment scale-up and the initiation of injection drug use: A dynamic modeling analysis. PLoS Medicine, 2019, 16, e1002973.	8.4	17
59	How to eliminate HCV infection by antiviral treatment. Journal of Hepatology, 2017, 67, 5-6.	3.7	16
60	Interim effect evaluation of the hepatitis C elimination programme in Georgia: a modelling study. The Lancet Global Health, 2020, 8, e244-e253.	6.3	16
61	Understanding and Addressing Hepatitis C Virus Reinfection Among Men Who Have Sex with Men. Infectious Disease Clinics of North America, 2018, 32, 395-405.	5.1	15
62	Modelling the impact of a national scaleâ€up of interventions on hepatitis C virus transmission among people who inject drugs in Scotland. Addiction, 2018, 113, 2118-2131.	3.3	15
63	Cost-effectiveness and budgetary impact of HCV treatment with direct-acting antivirals in India including the risk of reinfection. PLoS ONE, 2019, 14, e0217964.	2.5	14
64	Integrating HIV preâ€exposure prophylaxis and harm reduction among men who have sex with men and transgender women to address intersecting harms associated with stimulant use: a modelling study. Journal of the International AIDS Society, 2020, 23, e25495.	3.0	14
65	The contribution of unstable housing to HIV and hepatitis C virus transmission among people who inject drugs globally, regionally, and at country level: a modelling study. Lancet Public Health, The, 2022, 7, e136-e145.	10.0	14
66	Sustained Impact of the Coronavirus Disease 2019 Pandemic on Hepatitis C Virus Treatment Initiations in the United States. Clinical Infectious Diseases, 2022, 75, e955-e961.	5.8	14
67	Evaluating the impact of global fund withdrawal on needle and syringe provision, cost and use among people who inject drugs in Tijuana, Mexico: a costing analysis. BMJ Open, 2019, 9, e026298.	1.9	13
68	Scaling up screening and treatment for elimination of hepatitis C among men who have sex with men in the era of HIV pre-exposure prophylaxis. EClinicalMedicine, 2020, 19, 100217.	7.1	13
69	HCV treatment as prevention in prison: Key issues. Hepatology, 2015, 61, 402-403.	7.3	12
70	Modelling the potential prevention benefits of a treatâ€all hepatitis C treatment strategy at global, regional and country levels: A modelling study. Journal of Viral Hepatitis, 2019, 26, 1388-1403.	2.0	11
71	Modelling integrated antiretroviral treatment and harm reduction services on HIV and overdose among people who inject drugs in Tijuana, Mexico. Journal of the International AIDS Society, 2020, 23, e25493.	3.0	11
72	Articulating the Traumaâ€Informed Theory of Individual Health Behavior. Stress and Health, 2022, 38, 154-162.	2.6	11

#	Article	IF	Citations
73	Modeling the populationâ€level impact of opioid agonist treatment on mortality among people accessing treatment between 2001 and 2020 in New South Wales, Australia. Addiction, 2022, 117, 1338-1352.	3.3	11
74	Hepatitis C Virus Reinfection Following Direct-Acting Antiviral Treatment in the Prison Setting: The SToP-C Study. Clinical Infectious Diseases, 2022, 75, 1809-1819.	5.8	11
75	How costâ€effective is hepatitis C virus treatment for people who inject drugs?. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 590-592.	2.8	10
76	Cost-effectiveness of Antenatal Rescreening Among Pregnant Women for Hepatitis C in the United States. Clinical Infectious Diseases, 2021, 73, e3355-e3357.	5.8	10
77	What the HIV Pandemic Experience Can Teach the United States About the COVID-19 Response. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 86, 1-10.	2.1	10
78	Methods and indicators to validate country reductions in incidence of hepatitis C virus infection to elimination levels set by WHO. The Lancet Gastroenterology and Hepatology, 2022, 7, 353-366.	8.1	10
79	A gender lens is needed in hepatitis C elimination research. International Journal of Drug Policy, 2022, 103, 103654.	3.3	10
80	Chronic hepatitis B virus case-finding in UK populations born abroad in intermediate or high endemicity countries: an economic evaluation. BMJ Open, 2019, 9, e030183.	1.9	9
81	Evaluating the Prevention Benefit of HCV Treatment: Modeling the SToPâ€C Treatment as Prevention Study in Prisons. Hepatology, 2021, 74, 2366-2379.	7.3	9
82	Optimal Allocation of Resources in Female Sex Worker Targeted HIV Prevention Interventions: Model Insights from Avahan in South India. PLoS ONE, 2014, 9, e107066.	2.5	9
83	Costâ€effectiveness of the HepCATT intervention in specialist drug clinics to improve caseâ€finding and engagement with HCV treatment for people who inject drugs in England. Addiction, 2020, 115, 1509-1521.	3.3	8
84	Costâ€effectiveness of using hepatitis C viremic hearts for transplantation into HCVâ€negative recipients. American Journal of Transplantation, 2021, 21, 657-668.	4.7	8
85	Fatal overdose: Predicting to prevent. International Journal of Drug Policy, 2022, 104, 103677.	3.3	8
86	Overlapping substance using high-risk groups and infectious diseases: how dynamic modelling can evaluate risk and target HIV prevention. Addiction, 2016, 111, 1512-1515.	3.3	7
87	Is hepatitis C virus (HCV) elimination achievable among people who inject drugs in Tijuana, Mexico? A modeling analysis. International Journal of Drug Policy, 2021, 88, 102710.	3.3	7
88	Overlapping Key Populations and HIV Transmission in Tijuana, Mexico: A Modelling Analysis of Epidemic Drivers. AIDS and Behavior, 2021, 25, 3814-3827.	2.7	7
89	Estimating vaccination threshold and impact in the 2017â€“2019 hepatitis A virus outbreak among persons experiencing homelessness or who use drugs in Louisville, Kentucky, United States. Vaccine, 2021, 39, 7182-7190.	3.8	7
90	Hepatitis C virus prevention and treatment prioritizationâ€”ethical, economic and evidential dimensions of early rather than delayed treatment for people who inject drugs. Addiction, 2017, 112, 201-203.	3.3	6

#	Article	IF	Citations
91	Assessing HIV and overdose risks for people who use drugs exposed to compulsory drug abstinence programs (CDAP): A systematic review and meta-analysis. International Journal of Drug Policy, 2021, 96, 103401.	3.3	5
92	Hepatitis case finding among migrants in primary care. The Lancet Gastroenterology and Hepatology, 2019, 4, 3-4.	8.1	4
93	Cost and cost-effectiveness of a real-world HCV treatment program among HIV-infected individuals in Myanmar. BMJ Global Health, 2021, 6, e004181.	4.7	4
94	Costâ€effectiveness of hepatitis C virus (HCV) elimination strategies among people who inject drugs (PWID) in Tijuana, Mexico. Addiction, 2021, 116, 2734-2745.	3.3	4
95	Impact of cumulative incarceration and the postâ€release period on syringeâ€sharing among people who inject drugs in Tijuana, Mexico: a longitudinal analysis. Addiction, 2021, 116, 2724-2733.	3.3	4
96	Modeling Combination HCV Prevention among HIV-infected Men Who Have Sex With Men and People Who Inject Drugs. AIDS Reviews, 2017, 19, 97-104.	1.0	4
97	STI/HIV test result disclosure between female sex workers and their primary, non-commercial male partners in two Mexico-US border cities: a prospective study. Sexually Transmitted Infections, 2015, 91, 207-213.	1.9	3
98	What is required for achieving hepatitis C virus elimination in Singapore? A modeling study. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 1110-1117.	2.8	3
99	The costâ€effectiveness of caseâ€finding strategies for achieving hepatitis C elimination among men who have sex with men in the UK. Journal of Viral Hepatitis, 2021, 28, 897-908.	2.0	3
100	The estimated hepatitis C seroprevalence and key population sizes in San Diego in 2018. PLoS ONE, 2021, 16, e0251635.	2.5	3
101	What is needed to achieve HCV microelimination among HIV-infected populations in Andalusia, Spain: a modeling analysis. BMC Infectious Diseases, 2020, 20, 588.	2.9	2
102	Establishing a framework towards monitoring HCV microelimination among men who have sex with men living with HIV in Germany: A modeling analysis. PLoS ONE, 2022, 17, e0267853.	2.5	2
103	BRIDGING THE GAP BETWEEN PILOT AND SCALE-UP. Sexually Transmitted Diseases, 2021, Publish Ahead of Print, 59-66.	1.7	1
104	Screening for Sexually Transmitted Infections During Hepatitis C Treatment to Predict Reinfection Among People With HIV. Open Forum Infectious Diseases, 2021, 8, ofaa643.	0.9	1
105	Reply. Hepatology, 2016, 64, 1822-1823.	7.3	0
106	Hepatitis C Virus (HCV) Treatment as Prevention: Epidemic and Cost-Effectiveness Modeling. Handbook of Statistics, 2017, 37, 93-119.	0.6	0
107	Prisons can also improve drug user health in the community. Addiction, 2020, 115, 914-915.	3.3	0
108	The use of mathematical modeling to inform drug policy making. International Journal of Drug Policy, 2021, 88, 102759.	3.3	0

#	Article	IF	Citations
109	Discussion of article by Ellenberg and Morris. Statistics in Medicine, 2021, 40, 2511-2512.	1.6	0